United States

People: Abiomed Inc (ABMD.O)

ABMD.O on Nasdaq

20 Oct 2017
Change (% chg)

$2.41 (+1.40%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Rose, Eric 

Dr. Eric A. Rose, M.D. is an Independent Director of the Company. Dr. Rose has served as a director since August 2014 and previously served as a director from May 2007 to January 2012. He serves as Executive Chairman of SIGA Technologies, Inc., a developer of anti-viral drugs directed at potential agents of bioterror that filed voluntary proceedings under Chapter 11 of the United States Bankruptcy Code in September 2014 and exited from bankruptcy protection in April 2016. Dr. Rose served from 2007 to 2016 as Executive Vice President for Life Sciences at MacAndrews & Forbes and Chief Executive Officer of SIGA Technologies, Inc. Dr. Rose chaired the Department of Health Evidence & Policy at the Mount Sinai School of Medicine from 2008 to 2012, where he now serves as professor. From 1994 to 2007, he was Surgeon-in-Chief at New York-Presbyterian Hospital/Columbia and Chairman of the Department of Surgery at the Columbia University College of Physicians and Surgeons. A heart surgeon, researcher and entrepreneur, Dr. Rose helped grow Columbia’s Department of Surgery over the past 25 years while investigating, managing and developing complex medical technologies such as heart transplantation and new approaches to Alzheimer’s disease and bioterrorism. He has authored or co-authored more than 300 scientific publications and has received more than $25 million in NIH support for his research. Dr. Rose pioneered heart transplantation in children, performing the first successful pediatric heart transplant in 1984, and has investigated many alternatives to heart transplantation, including cross-species transplantation and man-made heart pumps. He received both his undergraduate and medical degrees from Columbia University.

Basic Compensation

Total Annual Compensation, USD 59,274
Restricted Stock Awards, USD 199,768
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 259,042

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Michael Minogue


Ian McLeod


David Weber


William Bolt


Andrew Greenfield


Michael Howley

As Of  30 Mar 2017